Home
Conditions
Multiple Sclerosis, Relapsing-Remitting

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

455 public trials 46 recruiting studies

Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis

NCT04567264

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +16 more
Locations: Ospedale Regionale di Lugano, Neurocenter of Southern Switzerland Lugano, Canton Ticino, Switzerland

View Trial Details

Completed

PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.

NCT03942952

Conditions: Acute Disseminated Encephalomyelitis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +33 more
Locations: University Texas Southwestern Dallas, Texas, United States

View Trial Details

Completed

Plegridy Satisfaction Study in Participants

NCT02587065

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: Research Site Arezzo, Italy

Research Site Bari, Italy

Research Site Cagliari, Italy

Research Site Cefalù, Italy

View all 30 locations

View Trial Details

Completed

Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP

NCT04221191

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations: Ch D'Agen Agen, France

CH d'Aix-en-Provence Aix-en-Provence, France

CHU Amiens Amiens, France

CHU D'amiens Amiens, France

View all 63 locations

View Trial Details

Completed

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

NCT04115488

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations: Grodno Regional Clinical Hospital Grodno, Belarus

Minsk City Clinical Hospital #5 Minsk, Belarus

Republican Research and Development Center for Neurology and Neurosurgery Minsk, Belarus

Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology Minsk, Belarus

View all 48 locations

View Trial Details

Completed

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

NCT04655222

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations: Research Site Göttingen, Germany

View Trial Details

Completed

Clinical Decision Support System (CADIMS) for MS Diagnostic

NCT03205280

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +8 more
Locations: Centre Hospitalier Bretagne Sud Lorient, France

Centre Hospitalier Universitaire de Rennes Rennes, France

Centre Hospitalier Rennes, France

Centre d'imagerie médicale de la découverte St-Malo, France

View Trial Details

Completed

Behavior and Activity Monitoring in MS

NCT03244696

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Behavior, +15 more
Locations: Department of Psychology, The Ohio State University Columbus, Ohio, United States

View Trial Details

Completed

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

NCT02988401

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +12 more
Locations: Johns Hopkins University School of Medicine Baltimore, Maryland, United States

View Trial Details

Completed

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016

Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations: The George Washignton University Washington D.C., District of Columbia, United States

View Trial Details

Multiple Sclerosis, Relapsing-Remitting

Multiple Sclerosis, Relapsing-Remitting trial results

Related conditions